Rejuvenate Bio CEO on Gene Therapy for Aging Pets and Humans
Rejuvenate Bio CEO Dan Oliver joins Chris Lustrino to discuss the company’s gene therapy platform for aging-related disease. A spinout from George Church’s lab at Harvard Medical School, Rejuvenate Bio is developing therapies designed to change gene expression profiles associated with aging rather than edit or replace a patient’s underlying genome. Dan explains how the company uses viral delivery to help the body produce beneficial proteins over time. The conversation explores Rejuvenate Bio’s dual strategy across animal health and human health. Dan explains why dogs offer both a meaningful commercial market and a scientifically useful path for developing aging-related therapies, especially because dogs age faster than humans and owners increasingly view pets as family members. Chris and Dan also discuss Rejuvenate Bio’s partnerships with animal health companies, its development and commercial milestone agreements, its recently closed round backed by Merck Animal Health, the FDA approval process for veterinary products, and the company’s long-term plan to generate first-in-human clinical data that could create major partnering, acquisition, or public market opportunities.



